Colorectal Cancer
Natera Minimal Residual Disease Test Predicts Oligometastatic CRC Patient Outcomes in New Study
Premium
Investigators analyzed blood samples from patients at two time points after curative-intent surgery, finding that ctDNA MRD status was highly predictive of outcome.
The company hopes to complete the trial in early 2022 and submit data to the FDA for approval of its assay, which could compete with Exact Sciences' Cologuard.
Oncocyte, Italian Foundation to Investigate DetermaIO in Colorectal Cancer
The Italian research group will evaluate the ability of Oncocyte's gene expression assay in samples from immunotherapy trials for advanced colorectal cancer patients.
USPSTF Now Recommends Colorectal Cancer Screening Beginning at Age 45
The US Preventive Services Task Force had previously recommended that average-risk adults begin colorectal cancer screening at age 50.
The data, while limited, indicate that the firm's blood-only assay may be able to match the performance of existing commercial tissue-informed competitors.